Sumitomo Dainippon Pharma Annual Report 2017

We aim for early maximizationof product value in each region.MarketingJapanese MarketFurther strengthen sales capacity in focus areasBuild a highly efcient sales organization that can exibly respond to changing local healthcare(Billions of yen)(forecast)(FY)2014201520162017Japanese Market Net Sales156.6146.5139.2140.8JapanChinaTRERIEF®IndicationsFeaturesParkinson’s diseaseParkinson’s disease drug with levodopa-enhancing effectAbout targetdiseaseAbout targetdiseaseApprox. 160,000 patients in Japan. Onset often affects those aged 50-65, with the rate of incidence increasing with age.Since no treatment currently exists for stopping the progression of the disease, appropriate pharmaceutical treatment or surgery is selected according to the severity of conditions.LONASEN®IndicationsFeaturesSchizophreniaDopamine D2 receptors and serotonin 5-HT2A receptors blockerAbout targetdiseaseAbout targetdiseaseApprox. 770,000 patients in Japan.On-going treatment to prevent recurrence is important since the disease tends to be chronic. Progress in new drug development and psychosocial care has raised the prospects of full and long-term recovery for nearly half of rst-time patients.AIMIX®IndicationsFeaturesHypertensionCombination product of irbesartan (AVAPRO®) and amlodipine besilate (AMLODIN®)About targetdiseaseApprox. 10,100,000 patients in Japan, with deaths due to hypertensive disease exceeding 6,000 people a year.The basic approach to treatment is lifestyle changes (exercise therapy, diet therapy) and pharmaceutical treatment. If the disease progresses, the strength and elasticity of vascular walls are lost and arteriosclerosis is accelerated.33Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#34